Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.

Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open. J Clin Oncol (2015) 1.07

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. Ther Adv Med Oncol (2016) 0.77

Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. Oncotarget (2016) 0.77

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC. Lung Cancer Int (2013) 0.77

Reply to E. Giovannetti et al. J Clin Oncol (2015) 0.75

Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer. Clin Lung Cancer (2016) 0.75

Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy. Cancer Med (2016) 0.75

Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthetase level. Onco Targets Ther (2016) 0.75

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. Br J Cancer (2016) 0.75

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression. PLoS One (2016) 0.75